Alleviation of pain in painful diabetic neuropathy

References

• Jensen TS, Baron R, Haanpaa M, et al. A new definition of neuropathic pain. Pain. 2011;152:2204–2205.
   PubMed Web of Science ®Google Scholar
• Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807–819.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173.
   PubMed Web of Science ®Google Scholar
• Alabdali M, Qrimli M, Barnett C, et al. Choosing drugs for the treatment of diabetic neuropathy. Expert Opin Pharmacother. 2015;16:1805–1814.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Majlath Z, Balog A, et al. Drug targets of migraine and neuropathy: treatment of hyperexcitability. CNS Neurol Disord Drug Targets. 2015;14:664–676.
   PubMed Web of Science ®Google Scholar
• Marmiroli P, Cavaletti G. Drugs for the treatment of peripheral neuropathies. Expert Opin Pharmacother. 2016;17:381–394. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26567516
   PubMed Web of Science ®Google Scholar
• Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015;156(Suppl 1):S104–S114.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study. Neurology. 1993;43:817–824.
   PubMed Web of Science ®Google Scholar
• MacDonald BK, Cockerell OC, Sander JW, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123(Pt 4):665–676.
   PubMed Web of Science ®Google Scholar
• Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45–56.
   PubMedGoogle Scholar
• Sadosky A, Mardekian J, Parsons B, et al. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29:212–217.
   PubMed Web of Science ®Google Scholar
• Smith SC, Lamping DL, Maclaine GD. Measuring health-related quality of life in diabetic peripheral neuropathy: a systematic review. Diabetes Res Clin Pract. 2012;96:261–270.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Csati A, et al. Prophylactic drug treatment of migraine in children and adolescents: an update. Curr Pain Headache Rep. 2016;20:1.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Majlath Z, et al. Migraine and neuropeptides. Neuropeptides. 2015;52:19–30.
   PubMed Web of Science ®Google Scholar
• Szok D, Csati A, Vecsei L, et al. Treatment of chronic migraine with onabotulinumtoxina: mode of action, efficacy and safety. Toxins (Basel). 2015;7:2659–2673.
   PubMed Web of Science ®Google Scholar
• Tajti J, Tuka B, Botz B, et al. Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. CNS Neurol Disord Drug Targets. 2015;14:540–553.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Jensen TS. Mechanisms of disease: mechanism-based classification of neuropathic pain-a critical analysis. Nat Clin Pract Neurol. 2006;2:107–115.
   PubMedGoogle Scholar
• Hirose M, Kuroda Y, Murata E. NGF/TrkA signaling as a therapeutic target for pain. Pain Pract. 2016;16:175–182.
   PubMed Web of Science ®Google Scholar
• Khan N, Smith MT. Neurotrophins and neuropathic pain: role in pathobiology. Molecules. 2015;20:10657–10688.
   PubMed Web of Science ®Google Scholar
• Baron R. Mechanisms of disease: neuropathic pain–a clinical perspective. Nat Clin Pract Neurol. 2006;2:95–106.
   PubMedGoogle Scholar
• Biggs JE, Lu VB, Stebbing MJ, et al. Is BDNF sufficient for information transfer between microglia and dorsal horn neurons during the onset of central sensitization? Mol Pain. 2010;6:44.
   PubMed Web of Science ®Google Scholar
• Calvo M, Dawes JM, Bennett DL. The role of the immune system in the generation of neuropathic pain. Lancet Neurol. 2012;11:629–642.
   PubMed Web of Science ®Google Scholar
• Sommer C. Painful neuropathies. Curr Opin Neurol. 2003;16:623–628.
   PubMed Web of Science ®Google Scholar
• Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–898.
   PubMed Web of Science ®Google Scholar
• Minett MS, Nassar MA, Clark AK, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun. 2012;3:791.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park CK, Chen G, et al. A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. Cell. 2014;157:1393–1404.
   PubMed Web of Science ®Google Scholar
• Kharatmal SB, Singh JN, Sharma SS. Voltage-gated sodium channels as therapeutic targets for treatment of painful diabetic neuropathy. Mini Rev Med Chem. 2015;15:1134–1147.
   PubMed Web of Science ®Google Scholar
• Zhang JL, Yang JP, Zhang JR, et al. Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. Brain Res. 2013;1493:13–18.
   PubMed Web of Science ®Google Scholar
• Galloway C, Chattopadhyay M. Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in Type 2 diabetes. Cytokine. 2013;63:1–5.
   PubMed Web of Science ®Google Scholar
• Trang T, Beggs S, Salter MW. Brain-derived neurotrophic factor from microglia: a molecular substrate for neuropathic pain. Neuron Glia Biol. 2011;7:99–108.
   PubMedGoogle Scholar
• Petrenko AB, Yamakura T, Baba H, et al. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003;97:1108–1116.
   PubMed Web of Science ®Google Scholar
• Beniczky S, Tajti J, Timea Varga E, et al. Evidence-based pharmacological treatment of neuropathic pain syndromes. J Neural Transm (Vienna). 2005;112:735–749.
   PubMed Web of Science ®Google Scholar
• Wagner AH, Coffman AC, Ainscough BJ, et al. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 2016;44:D1036–D1044.
   PubMedGoogle Scholar
• Javed S, Petropoulos IN, Alam U, et al. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6:15–28.
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113–e88.
   PubMed Web of Science ®Google Scholar
• Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American academy of neurology, the American association of neuromuscular and electrodiagnostic medicine, and the American academy of physical medicine and rehabilitation. Neurology. 2011;76:1758–1765.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
   PubMed Web of Science ®Google Scholar
• Fangmann P, Assion HJ, Juckel G, et al. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. J Clin Psychopharmacol. 2008;28:1–4.
   PubMed Web of Science ®Google Scholar
• Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013;9:105–115.
   PubMed Web of Science ®Google Scholar
• Smith TR. Duloxetine in diabetic neuropathy. Expert Opin Pharmacother. 2006;7:215–223.
   PubMed Web of Science ®Google Scholar
• Ryan NM. A review on the efficacy and safety of gabapentin in the treatment of chronic cough. Expert Opin Pharmacother. 2015;16:135–145.
   PubMed Web of Science ®Google Scholar
• Reinen J, Postma G, Tump C, et al. Application of a cocktail approach to screen cytochrome P450 BM3 libraries for metabolic activity and diversity. Anal Bioanal Chem. 2016;408:1425–1443.
   PubMed Web of Science ®Google Scholar
• Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs. 2001;15:643–669.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. Br J Clin Pharmacol. 1999;48:71–78.
   PubMed Web of Science ®Google Scholar
• Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2012;52:6–17.
   PubMed Web of Science ®Google Scholar
• Punke MA, Friederich P. Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg. 2007;104:1256–1264. tables of contents.
   PubMed Web of Science ®Google Scholar
• Jang SW, Liu X, Chan CB, et al. Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol. 2009;16:644–656.
   PubMed Web of Science ®Google Scholar
• Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10:1457–1489.
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014;11:37–42.
   PubMedGoogle Scholar
• Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23:523–541.
   PubMed Web of Science ®Google Scholar
• Knadler MP, Lobo E, Chappell J, et al. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50:281–294.
   PubMed Web of Science ®Google Scholar
• Barman Balfour JA, Jarvis B. Venlafaxine extended-release: a review of its clinical potential in the management of generalised anxiety disorder. CNS Drugs. 2000;14:483–503.
   Web of Science ®Google Scholar
• Curran MP, Wagstaff AJ. Gabapentin: in postherpetic neuralgia. CNS Drugs. 2003;17:975–982.
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)–part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52:927–966.
   PubMed Web of Science ®Google Scholar
• Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16:E705–E714.
   PubMed Web of Science ®Google Scholar
• Tjandrawinata RR, Setiawati E, Putri RS, et al. Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. Clin Pharmacol. 2015;7:69–75.
   PubMedGoogle Scholar
• Hicks JK, Swen JJ, Thorn CF, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93:402–408.
   PubMed Web of Science ®Google Scholar
• Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250–1256.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31:542–559.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118.
   PubMed Web of Science ®Google Scholar
• Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD007938.
   PubMed Web of Science ®Google Scholar
• Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29:26–48.
   PubMed Web of Science ®Google Scholar
• Gore M, Dukes E, Rowbotham D, et al. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Pract. 2006;6:265–272.
   PubMedGoogle Scholar
• Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;7:CD008242.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Beedle EE, Findlay J, et al. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2003;13:4477–4480.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11:1475–1493.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., Raffa RB, Taylor R Jr., et al. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract. 2013;13:239–252.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol. 2010;23:417–422.
   PubMed Web of Science ®Google Scholar
• Salat K, Moniczewski A, Librowski T. Nitrogen, oxygen or sulfur containing heterocyclic compounds as analgesic drugs used as modulators of the nitroxidative stress. Mini Rev Med Chem. 2013;13:335–352.
   PubMed Web of Science ®Google Scholar
• Wang SY, Calderon J, Kuo Wang G. Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology. 2010;113:655–665.
   PubMed Web of Science ®Google Scholar
• Kinoshita J, Takahashi Y, Watabe AM, et al. Impaired noradrenaline homeostasis in rats with painful diabetic neuropathy as a target of duloxetine analgesia. Mol Pain. 2013;9:59.
   PubMed Web of Science ®Google Scholar
• Maciukiewicz M, Marshe VS, Tiwari AK, et al. Genetic variation in IL-1beta, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder. Pharmacogenomics. 2015;16:1919–1929.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Fijal B, Dharia S, et al. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J. 2013;13:280–285.
   PubMed Web of Science ®Google Scholar
• de Leon J, Susce MT, Murray-Carmichael E. The amplichip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther. 2006;10:135–151.
   PubMed Web of Science ®Google Scholar
• de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47:75–85.
   PubMed Web of Science ®Google Scholar
• Redrobe JP, Bourin M, Colombel MC, et al. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl). 1998;138:1–8.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects–a possible opioid involvement in severe depression? J Mol Neurosci. 2002;18:143–149.
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Narasimhan S, Rickels K, et al. Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2013;210:1299–1300.
   PubMed Web of Science ®Google Scholar
• Gallagher HC, Gallagher RM, Butler M, et al. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;8:CD011091.
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697–706.
   PubMed Web of Science ®Google Scholar
• Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy. 2004;24:621–629.
   PubMed Web of Science ®Google Scholar
• Bellows BK, Dahal A, Jiao T, et al. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J Pain Palliat Care Pharmacother. 2012;26:153–164.
   PubMedGoogle Scholar
• Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of cochrane reviews. Cochrane Database Syst Rev. 2013;11:CD010567.
   PubMed Web of Science ®Google Scholar
• Schreiber AK, Nones CF, Reis RC, et al. Diabetic neuropathic pain: physiopathology and treatment. World J Diabetes. 2015;6:432–444.
   PubMed Web of Science ®Google Scholar
• Stacey BR. Gabapentin: a viewpoint by Brett R. Stacey. CNS Drugs. 2003;17:983–984.
   PubMed Web of Science ®Google Scholar
• Chen C. Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. Eur J Clin Pharmacol. 2013;69:1809–1817.
   PubMed Web of Science ®Google Scholar
• Zhang L, Rainka M, Freeman R, et al. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013;14:590–603.
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)–Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013;52:1045–1061.
   PubMed Web of Science ®Google Scholar
• Yang M, Qian C, Liu Y. Suboptimal treatment of diabetic peripheral neuropathic pain in the United States. Pain Med. 2015;16:2075–2083.
   PubMed Web of Science ®Google Scholar
• Mico JA, Prieto R. Elucidating the mechanism of action of pregabalin: alpha(2)delta as a therapeutic target in anxiety. CNS Drugs. 2012;26:637–648.
   PubMed Web of Science ®Google Scholar
• Froestl W. An historical perspective on GABAergic drugs. Future Med Chem. 2011;3:163–175.
   PubMed Web of Science ®Google Scholar
• Kanbayashi Y, Onishi K, Hosokawa T. Factors predicting adverse events associated with pregabalin administered for neuropathic pain relief. Pain Res Manag. 2014;19:e164–e167.
   PubMed Web of Science ®Google Scholar
• Hall GC, Morant SV, Carroll D, et al. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Fam Pract. 2013;14:28.
   PubMed Web of Science ®Google Scholar
• Purwata TE. High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J Pain Res. 2011;4:169–175.
   PubMedGoogle Scholar
• Mikaili P, Moloudizargari M, Aghajanshakeri S. Treatment with topical nitroglycerine may promote the healing process of diabetic foot ulcers. Med Hypotheses. 2014;83:172–174.
   PubMed Web of Science ®Google Scholar
• Huang LY, Tsui DY, Williams CM, et al. The furoxan nitric oxide donor, PRG150, evokes dose-dependent analgesia in a rat model of Painful Diabetic Neuropathy (PDN). Clin Exp Pharmacol Physiol. 2015;42:921–929.
   Web of Science ®Google Scholar
• Motawi TK, Rizk SM, Ibrahim IA, et al. Alterations in circulating angiogenic and anti-angiogenic factors in type 2 diabetic patients with neuropathy. Cell Biochem Funct. 2014;32:155–163.
   PubMed Web of Science ®Google Scholar
• Varani K, Vincenzi F, Targa M, et al. Repeated dosing with NCX1404, a nitric oxide-donating pregabalin, re-establishes normal nociceptive responses in mice with streptozotocin-induced painful diabetic neuropathy. J Pharmacol Exp Ther. 2016;357:240–247.
   PubMed Web of Science ®Google Scholar
• Sayin R, Aslan M, Kucukoglu ME, et al. Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine. 2014;47:146–151.
   PubMed Web of Science ®Google Scholar
• Agrawal RP, Jain S, Goyal S, et al. A clinical trial of nitrosense patch for the treatment of patients with painful diabetic neuropathy. J Assoc Physicians India. 2014;62:385–390.
   PubMedGoogle Scholar
• Liu Y, Jann M, Vandenberg C, et al. Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: application to the analysis of drug-drug interaction. J Chromatogr A. 2015;1420:119–128.
   PubMed Web of Science ®Google Scholar
• Bray N. Analgesia: anti-itch and anti-ouch antibody. Nat Rev Drug Discov. 2014;13:574–575.
   PubMed Web of Science ®Google Scholar
• Orestes P, Osuru HP, McIntire WE, et al. Reversal of neuropathic pain in diabetes by targeting glycosylation of Ca(V)3.2 T-type calcium channels. Diabetes. 2013;62:3828–3838.
   PubMed Web of Science ®Google Scholar
• Dina OA, Hucho T, Yeh J, et al. Primary afferent second messenger cascades interact with specific integrin subunits in producing inflammatory hyperalgesia. Pain. 2005;115:191–203.
   PubMed Web of Science ®Google Scholar
• Dina OA, Parada CA, Yeh J, et al. Integrin signaling in inflammatory and neuropathic pain in the rat. Eur J Neurosci. 2004;19:634–642.
   PubMed Web of Science ®Google Scholar
• Ferrari LF, Levine JD. Plasma membrane mechanisms in a preclinical rat model of chronic pain. J Pain. 2015;16:60–66.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015;23(Suppl 1):S8–S17.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23(Suppl 1):S18–S21.
   PubMed Web of Science ®Google Scholar
• Wang H, Romano G, Frustaci ME, et al. Fulranumab for treatment of diabetic peripheral neuropathic pain: a randomized controlled trial. Neurology. 2014;83:628–637.
   PubMed Web of Science ®Google Scholar
• Bramson C, Herrmann DN, Carey W, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16:1163–1176.
   PubMed Web of Science ®Google Scholar
• Brederson JD, Strakhova M, Mills C, et al. A monoclonal antibody against the receptor for advanced glycation end products attenuates inflammatory and neuropathic pain in the mouse. Eur J Pain. 2016;20:607–614. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=A+monoclonal+antibody+against+the+receptor+for+advanced+glycation+end+products+attenuates+inflammatory+and+neuropathic+pain+in+the+mouse
   PubMed Web of Science ®Google Scholar
• Yao CY, Weng ZL, Zhang JC, et al. Interleukin-17A acts to maintain neuropathic pain through activation of CaMKII/CREB signaling in spinal neurons. Mol Neurobiol. 2015 Jul 14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=Interleukin-17A+acts+to+maintain+neuropathic+pain+through+activation+of+CaMKII%2FCREB+signaling+in+spinal+neurons. [Epub ahead of print]
   Web of Science ®Google Scholar
• Zhang FF, Morioka N, Harano S, et al. Perineural expression of high-mobility group box-1 contributes to long-lasting mechanical hypersensitivity via matrix metalloproteinase-9 upregulation in mice with painful peripheral neuropathy. J Neurochem. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26578177. doi:10.1111/jnc.13434. [Epub ahead of print]
   Web of Science ®Google Scholar
• Lakhan SE, Velasco DN, Tepper D. Botulinum toxin-A for painful diabetic neuropathy: a meta-analysis. Pain Med. 2015;16:1773–1780.
   PubMed Web of Science ®Google Scholar
• Jordt SE, Ehrlich BE. TRP channels in disease. Subcell Biochem. 2007;45:253–271.
   PubMedGoogle Scholar
• Payrits M, Saghy E, Matyus P, et al. A novel 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime compound is a potent transient receptor potential Ankyrin 1 and Vanilloid 1 (TRPA1 and V1) receptor antagonist. Neuroscience. 2016;324:151–162.
   PubMed Web of Science ®Google Scholar
• Burness CB, McCormack PL. Capsaicin 8 % patch: a review in peripheral neuropathic pain. Drugs. 2016;76:123–134.
   PubMed Web of Science ®Google Scholar
• Othman AA, Nothaft W, Awni WM, et al. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials. J Clin Pharmacol. 2012;52:1028–1041.
   PubMed Web of Science ®Google Scholar
• Manitpisitkul P, Mayorga A, Shalayda K, et al. Safety, tolerability and pharmacokinetic and pharmacodynamic learnings from a double-blind, randomized, placebo-controlled, sequential group first-in-human study of the TRPV1 antagonist, JNJ-38893777, in healthy men. Clin Drug Investig. 2015;35:353–363.
   PubMed Web of Science ®Google Scholar
• Preti D, Saponaro G, Szallasi A. Transient receptor potential ankyrin 1 (TRPA1) antagonists. Pharm Pat Anal. 2015;4:75–94.
   PubMed Web of Science ®Google Scholar
• de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014;155:2426–2431.
   PubMed Web of Science ®Google Scholar